Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer hope: new combo aims to stop tumor growth

NCT ID NCT07153445

Disease control Sponsor: Fundación GECP Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called atezolizumab (Tecentriq) plus standard chemotherapy in 97 people with stage III non-small cell lung cancer. After initial treatment, some may have surgery, while others continue on atezolizumab. The goal is to see if this approach helps keep the cancer from growing or coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq) plus paclitaxel and carboplatin chemotherapy
What this could lead to
If successful, this could offer a new treatment option that delays cancer progression and improves survival for people with stage III non-small cell lung cancer.
What could go wrong
This is a phase II trial with only 97 participants, so results are preliminary. The combination may cause serious side effects, and not all patients will benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 97 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

May 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously untreated patients with histologically- or cytologically- documented Non Small-Cell Lung Cancer (NSCLC) who present stage IIIA - IIIB disease (according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) * Confirm the absence of distant disease * ECOG (Performance status) 0-1 * Adequate hematologic and organ function * All patients are notified of the investigational nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention * Adequate lung function * Patients aged \> 18 years * For female patients of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception * For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form of contraception * Oral contraception should always be combined with an additional contraceptive method * Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 8 days prior to initiation of study drug. * Patient capable of proper therapeutic compliance and accessible for correct follow-up Exclusion Criteria: * Patients mutation or an amplification in the EGFRgene, ALK fusion oncogene. * Known STK-11 ligand alterations, MDM2 amplifications or ROS1 translocations. * Weight loss \>10% within the previous 3 months. * Patients that receive previous treatment with antineoplasic drugs, chest radiotherapy, or previous surgery for lung cancer. * Malignancies other than Non Small-Cell Lung Cancer (NSCLC) within 3 years prior to enrolment * Pleural or pericardial effusion * Known hypersensitivity or allergy to atezolizumab formulation. * History of autoimmune disease or lung disease * Positive test for human immunodeficiency viruses (HIV) * Patients with active hepatitis B or hepatitis C or psitive for hepatitis C virus. * Active tuberculosis. * Symptomatic neuropathy grade \> 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 * Severe infections within 4 weeks prior to be included in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer Stage IIIA lung cancer Stage IIIB lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Hospitalario de Navarra

    RECRUITING

    Pamplona, Pamplona, 31008, Spain

  • Hospital De Basurto

    RECRUITING

    Bilbao, Bilbao, 48013, Spain

  • Hospital General Universitario Dr. Balmis de Alicante

    RECRUITING

    Alicante, Alicante, 03010, Spain

  • Hospital General Universitario de Valencia

    RECRUITING

    Valencia, Valencia, 46014, Spain

  • Hospital Parc Taulí

    RECRUITING

    Barcelona, Barcelona, 08208, Spain

  • Hospital Univ. De Jerez De La Frontera

    RECRUITING

    Jerez de la Frontera, Cadiz, 11407, Spain

  • Hospital Universitari Sant Joan de Reus

    RECRUITING

    Reus, Tarragona, 43204, Spain

  • Hospital Universitari Son Llatzer

    RECRUITING

    Palma de Mallorca, Palma de Mallorca, 07198, Spain

  • Hospital Universitari Vall d' Hebron

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitari de Gran Canària Doctor Negrín

    RECRUITING

    Las Palmas de Gran Canaria, Las Palmas, 35010, Spain

  • Hospital Universitario Clinico San Cecilio

    RECRUITING

    Granada, Granada, 18007, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    NOT_YET_RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario Lucus Augusti

    RECRUITING

    Lugo, Lugo, 27003, Spain

  • Hospital Universitario Nuestra Señora La Candelaria

    RECRUITING

    Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38009, Spain

  • Hospital Universitario Puerta de Hierro

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Salamanca

    RECRUITING

    Salamanca, Salamanca, 37007, Spain

  • Hospital Universitario Virgen Del Rocio

    RECRUITING

    Seville, Sevilla, 41013, Spain

  • Hospital de la Santa Creu i Sant Pau

    RECRUITING

    Barcelona, Barcelona, 08041, Spain

  • Hospitalario Universitario A Coruña

    RECRUITING

    A Coruña, La Coruña, 15006, Spain

  • ICO Badalona, Hospital Germans Trias i Pujol

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • ICO Girona, Hospital Josep Trueta

    RECRUITING

    Girona, Girona, 17007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.